• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰腺癌的立体定向体部放射治疗——批判性综述与实践考量

Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration.

作者信息

Burkoň Petr, Trna Jan, Slávik Marek, Němeček Radim, Kazda Tomáš, Pospíšil Petr, Dastych Milan, Eid Michal, Novotný Ivo, Procházka Tomáš, Vrzal Miroslav

机构信息

Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 57 Brno, Czech Republic.

Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.

出版信息

Biomedicines. 2022 Oct 4;10(10):2480. doi: 10.3390/biomedicines10102480.

DOI:10.3390/biomedicines10102480
PMID:36289742
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9599229/
Abstract

Pancreatic cancer is the third leading cause of cancer death in the developed world and is predicted to become the second by 2030. A cure may be achieved only with surgical resection of an early diagnosed disease. Surgery for more advanced disease is challenging and can be contraindicated for many reasons. Neoadjuvant therapy may improve the probability of achieving R0 resection. It consists of systemic treatment followed by radiation therapy applied concurrently or sequentially with cytostatics. A novel approach to irradiation, stereotactic body radiotherapy (SBRT), has the potential to improve treatment results. SBRT can deliver higher doses of radiation to the tumor in only a few treatment fractions. It has attracted significant interest for pancreatic cancer patients, as it is completed quickly, requires less time away from full-dose chemotherapy, and is well-tolerated than conventional radiotherapy. In this review, we aim to provide the reader with a basic overview of current evidence for SBRT indications in the treatment of pancreatic tumors. In the second part of the review, we focus on practical information with respect to SBRT treatment plan preparation the performance of such therapy. Finally, we discuss future directions related to the use of magnetic resonance linear accelerators.

摘要

胰腺癌是发达国家癌症死亡的第三大主要原因,预计到2030年将成为第二大原因。只有通过手术切除早期诊断的疾病才能实现治愈。针对更晚期疾病的手术具有挑战性,并且由于多种原因可能被禁忌。新辅助治疗可能会提高实现R0切除的概率。它包括全身治疗,然后是与细胞抑制剂同时或序贯应用的放射治疗。一种新的放射治疗方法,立体定向体部放射治疗(SBRT),有可能改善治疗效果。SBRT仅在少数几次治疗分割中就能向肿瘤输送更高剂量的辐射。它引起了胰腺癌患者的极大兴趣,因为它完成得很快,需要较少的时间中断全剂量化疗,并且比传统放疗耐受性更好。在本综述中,我们旨在为读者提供关于SBRT在胰腺肿瘤治疗中适应证的当前证据的基本概述。在综述的第二部分,我们关注与SBRT治疗计划准备以及这种治疗的实施相关的实用信息。最后,我们讨论与磁共振直线加速器使用相关的未来方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa9/9599229/30b558cf6d0e/biomedicines-10-02480-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa9/9599229/0820f0e85e33/biomedicines-10-02480-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa9/9599229/44d9660e33a9/biomedicines-10-02480-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa9/9599229/30b558cf6d0e/biomedicines-10-02480-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa9/9599229/0820f0e85e33/biomedicines-10-02480-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa9/9599229/44d9660e33a9/biomedicines-10-02480-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa9/9599229/30b558cf6d0e/biomedicines-10-02480-g003.jpg

相似文献

1
Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration.胰腺癌的立体定向体部放射治疗——批判性综述与实践考量
Biomedicines. 2022 Oct 4;10(10):2480. doi: 10.3390/biomedicines10102480.
2
Stereotactic Body Radiotherapy - Current Indications.立体定向体部放射治疗——当前适应症
Klin Onkol. 2019 Winter;32(1):10-24. doi: 10.14735/amko201910.
3
Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma.局部立体定向放射治疗新辅助治疗局部晚期不可切除胰腺癌
Acta Oncol. 2019 Sep;58(9):1259-1266. doi: 10.1080/0284186X.2019.1631472. Epub 2019 Jun 25.
4
MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC).MR 引导自适应立体定向体部放疗(SBRT)治疗转移性胰腺导管腺癌(mPDAC)疼痛的初步研究:一项开放、随机、多中心、平行组临床试验(MASPAC)。
Radiat Oncol. 2022 Jan 25;17(1):18. doi: 10.1186/s13014-022-01988-6.
5
A Novel Neoadjuvant Therapy for Operable Locally Invasive Non-Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574).一种用于可手术的局部浸润性非小细胞肺癌的新型新辅助疗法。新辅助立体定向体部放射治疗的I期研究。LINNEARRE I(NCT02433574)。
Clin Lung Cancer. 2017 Jul;18(4):436-440.e1. doi: 10.1016/j.cllc.2017.01.007. Epub 2017 Jan 31.
6
Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions.多模态治疗后孤立性局部复发性胰腺癌行立体定向体部放射治疗的新治疗选择:来自两家机构的经验。
J Gastrointest Oncol. 2013 Dec;4(4):343-51. doi: 10.3978/j.issn.2078-6891.2013.044.
7
Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer.五分割立体定向体部放射治疗(SBRT)联合化疗用于转移性胰腺癌的局部治疗
J Gastrointest Cancer. 2018 Jun;49(2):116-123. doi: 10.1007/s12029-016-9909-2.
8
Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer.立体定向体部放疗治疗胰腺癌:最大限度控制肿瘤并减少并发症。
Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):206-216. doi: 10.1016/j.ijrobp.2020.11.017. Epub 2020 Dec 24.
9
Hypofractionated radiotherapy in pancreatic cancer: Lessons from the past in the era of stereotactic body radiation therapy.胰腺癌的大分割放疗:立体定向体部放疗时代的既往经验教训
Crit Rev Oncol Hematol. 2016 Jul;103:49-61. doi: 10.1016/j.critrevonc.2016.05.003. Epub 2016 May 12.
10
Stereotactic radiotherapy and the potential role of magnetic resonance-guided adaptive techniques for pancreatic cancer.立体定向放疗和磁共振引导自适应技术在胰腺癌治疗中的潜在作用。
World J Gastroenterol. 2022 Feb 21;28(7):745-754. doi: 10.3748/wjg.v28.i7.745.

引用本文的文献

1
Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: Clinical Usefulness and Limitations.根据CAP分级系统评估新辅助治疗后胰腺导管腺癌的肿瘤退缩和生存结果:临床实用性和局限性
Ann Surg Oncol. 2025 Aug 26. doi: 10.1245/s10434-025-18123-w.
2
Neoadjuvant Stereotactic Ablative Radiotherapy in Pancreatic Ductal Adenocarcinoma: A Review of Perioperative and Long-Term Outcomes.胰腺导管腺癌的新辅助立体定向消融放疗:围手术期及长期结局综述
Diseases. 2025 Jul 8;13(7):214. doi: 10.3390/diseases13070214.
3
The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was independent of intratumoral vascularization.

本文引用的文献

1
Pain Relief after Stereotactic Radiotherapy of Pancreatic Adenocarcinoma: An Updated Systematic Review.立体定向放疗治疗胰腺腺癌后的疼痛缓解:一项更新的系统评价。
Curr Oncol. 2022 Apr 11;29(4):2616-2629. doi: 10.3390/curroncol29040214.
2
Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study.立体定向磁共振引导下的胰腺癌放疗:前瞻性注册研究中自适应放疗的剂量学优势及初步临床结果
Front Oncol. 2022 Mar 9;12:842402. doi: 10.3389/fonc.2022.842402. eCollection 2022.
3
MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
新辅助放化疗对可切除胰腺癌的疗效与肿瘤内血管生成无关。
BMC Gastroenterol. 2025 Jul 19;25(1):526. doi: 10.1186/s12876-025-04108-2.
4
Real-Time Adaptive Respiratory Motion Compensation With Stent-Based Tracking.基于支架跟踪的实时自适应呼吸运动补偿
Cureus. 2025 May 28;17(5):e84971. doi: 10.7759/cureus.84971. eCollection 2025 May.
5
CT imaging findings following treatment with combination SBRT and chemotherapy versus stand-alone chemotherapy for locally advanced pancreatic adenocarcinoma.立体定向体部放疗(SBRT)联合化疗与单纯化疗治疗局部晚期胰腺腺癌后的CT影像表现
Abdom Radiol (NY). 2025 Jun 19. doi: 10.1007/s00261-025-05066-9.
6
Recent Advances and Challenges in the Treatment of Advanced Pancreatic Cancer: An Update on Completed and Ongoing Clinical Trials.晚期胰腺癌治疗的最新进展与挑战:已完成及正在进行的临床试验综述
Cancers (Basel). 2025 Apr 14;17(8):1319. doi: 10.3390/cancers17081319.
7
Feasibility and safety study of ultra-hypofractionated neoadjuvant radiotherapy to margins-at-risk in retroperitoneal sarcoma.腹膜后肉瘤累及高危边缘的超分割新辅助放疗的可行性和安全性研究
Radiat Oncol J. 2025 Mar;43(1):6-12. doi: 10.3857/roj.2024.00297. Epub 2025 Jan 15.
8
Dose-Escalated SBRT for Borderline and Locally Advanced Pancreatic Cancer: Resectability Rate and Pathological Results of a Multicenter Prospective Study.剂量递增的立体定向体部放疗用于临界可切除及局部进展期胰腺癌:一项多中心前瞻性研究的可切除率及病理结果
Cancers (Basel). 2025 Jan 9;17(2):191. doi: 10.3390/cancers17020191.
9
Unraveling Pancreatic Cancer: Epidemiology, Risk Factors, and Global Trends.解析胰腺癌:流行病学、风险因素及全球趋势
Cureus. 2024 Nov 1;16(11):e72816. doi: 10.7759/cureus.72816. eCollection 2024 Nov.
10
Clinical outcomes of preservation versus resection of portal/superior mesenteric vein during pancreaticoduodenectomy in pancreatic cancer patients who respond to neoadjuvant treatment: a retrospective cohort study.新辅助治疗有反应的胰腺癌患者在胰十二指肠切除术中门静脉/肠系膜上静脉保留与切除的临床结局:一项回顾性队列研究
Int J Surg. 2024 Nov 1;110(11):7150-7158. doi: 10.1097/JS9.0000000000002034.
磁共振引导自适应与 ITV 基础立体定向体部放疗治疗肝转移瘤(MAESTRO):一项随机对照的 II 期临床试验。
Radiat Oncol. 2022 Mar 27;17(1):59. doi: 10.1186/s13014-022-02033-2.
4
Stereotactic radiotherapy and the potential role of magnetic resonance-guided adaptive techniques for pancreatic cancer.立体定向放疗和磁共振引导自适应技术在胰腺癌治疗中的潜在作用。
World J Gastroenterol. 2022 Feb 21;28(7):745-754. doi: 10.3748/wjg.v28.i7.745.
5
Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial.多药化疗联合立体定向体部放疗治疗不可切除胰腺腺癌患者的前瞻性非随机对照试验
Pract Radiat Oncol. 2022 Nov-Dec;12(6):511-523. doi: 10.1016/j.prro.2022.02.009. Epub 2022 Mar 17.
6
Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity.新辅助立体定向体部放疗联合化疗对比单纯化疗用于不可切除或局部进展期胰腺癌患者可改善病理缓解率且不增加围手术期毒性
Ann Surg Oncol. 2022 Apr;29(4):2456-2468. doi: 10.1245/s10434-021-11202-8. Epub 2022 Feb 7.
7
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.可切除和边缘可切除胰腺癌的新辅助放化疗与 upfront 手术比较:荷兰随机 PREOPANC 试验的长期结果。
J Clin Oncol. 2022 Apr 10;40(11):1220-1230. doi: 10.1200/JCO.21.02233. Epub 2022 Jan 27.
8
Lipidomic profiling of human serum enables detection of pancreatic cancer.人血清脂质组学分析可用于胰腺癌检测。
Nat Commun. 2022 Jan 10;13(1):124. doi: 10.1038/s41467-021-27765-9.
9
Stereotactic body radiotherapy of lymph node metastases under MR-guidance: First clinical results and patient-reported outcomes.磁共振引导下淋巴结转移立体定向体部放疗:初步临床结果和患者报告的结局。
Strahlenther Onkol. 2022 Jan;198(1):56-65. doi: 10.1007/s00066-021-01834-w. Epub 2021 Sep 1.
10
Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer.立体定向体部放射治疗前基准标记放置对胰腺癌患者临床结局的影响
Adv Radiat Oncol. 2020 Nov 23;6(2):100621. doi: 10.1016/j.adro.2020.11.006. eCollection 2021 Mar-Apr.